KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  Jason J. Corneveaux,et al.  Whole transcriptome profiling of the human hippocampus suggests an involvement of the KIBRA rs17070145 polymorphism in differential activation of the MAPK signaling pathway , 2017, Hippocampus.

[3]  F. Pasquier,et al.  Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer’s disease: A review , 2016, Ageing Research Reviews.

[4]  R. Huganir,et al.  Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss , 2016, Neuron.

[5]  M. Jorge Cardoso,et al.  Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis , 2016, Neurobiology of Aging.

[6]  D. Rujescu,et al.  Impact of KIBRA Polymorphism on Memory Function and the Hippocampus in Older Adults , 2016, Neuropsychopharmacology.

[7]  P. Schofield,et al.  Investigating the influence of KIBRA and CLSTN2 genetic polymorphisms on cross-sectional and longitudinal measures of memory performance and hippocampal volume in older individuals , 2015, Neuropsychologia.

[8]  Kristen M. Kennedy,et al.  BDNF val66met polymorphism affects aging of multiple types of memory , 2015, Brain Research.

[9]  F. Lou,et al.  KIBRA genetic polymorphism and cognitive dysfunction in depression , 2015, Psychiatry Research.

[10]  P. Snyder,et al.  APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease , 2015, Neurobiology of Aging.

[11]  C. Rowe,et al.  Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.

[12]  P. Snyder,et al.  APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease , 2014, Molecular Psychiatry.

[13]  Nandini Raghavan,et al.  Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. , 2015, Journal of Alzheimer's disease : JAD.

[14]  J. Vickers,et al.  KIBRA gene polymorphism has no association with verbal or visual episodic memory performance , 2014, Front. Aging Neurosci..

[15]  C. Rowe,et al.  COMPARISON OF THREE NORMATIVE DATA CORRECTION APPROACHES: A CROSS-SECTIONAL EVALUATION IN THE AIBL STUDY , 2014, Alzheimer's & Dementia.

[16]  Keith A. Johnson,et al.  GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD , 2014, Alzheimer's & Dementia.

[17]  A. Saykin,et al.  APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  Fabio Sambataro,et al.  WWC1 Genotype Modulates Age-Related Decline in Episodic Memory Function Across the Adult Life Span , 2014, Biological Psychiatry.

[19]  P. Nathan,et al.  Effects of the KIBRA Single Nucleotide Polymorphism on Synaptic Plasticity and Memory: A Review of the Literature , 2014, Current neuropharmacology.

[20]  C. Rowe,et al.  Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.

[21]  P. Snyder,et al.  BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease , 2013, Neurobiology of Aging.

[22]  Christian F. Doeller,et al.  Aging and KIBRA/WWC1 genotype affect spatial memory processes in a virtual navigation task , 2013, Hippocampus.

[23]  C. Rowe,et al.  Aβ amyloid, cognition, and APOE genotype in healthy older adults , 2013, Alzheimer's & Dementia.

[24]  C. Rowe,et al.  Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing , 2013, Molecular Psychiatry.

[25]  Jurgen Fripp,et al.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. , 2013, JAMA neurology.

[26]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[27]  M. Jorge Cardoso,et al.  Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials , 2013, PloS one.

[28]  Martin Lövdén,et al.  Genetic effects on old-age cognitive functioning: a population-based study. , 2013, Psychology and aging.

[29]  C. Rowe,et al.  Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.

[30]  Lars-Göran Nilsson,et al.  KIBRA Polymorphism Is Related to Enhanced Memory and Elevated Hippocampal Processing , 2011, The Journal of Neuroscience.

[31]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[32]  Ronald C. Petersen,et al.  Association of common KIBRA variants with episodic memory and AD risk , 2011, Neurobiology of Aging.

[33]  H Wersching,et al.  Impact of Common KIBRA Allele on Human Cognitive Functions , 2011, Neuropsychopharmacology.

[34]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[35]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[36]  Takashi Morihara,et al.  Association study of KIBRA gene with memory performance in a Japanese population , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[37]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[38]  D. D. de Quervain,et al.  Fine-mapping of the brain-derived neurotrophic factor (BDNF) gene supports an association of the Val66Met polymorphism with episodic memory. , 2010, The international journal of neuropsychopharmacology.

[39]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[40]  Richard J. Caselli,et al.  Evidence for an association between KIBRA and late-onset Alzheimer's disease , 2010, Neurobiology of Aging.

[41]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[42]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[43]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[44]  Ian J. Deary,et al.  Association of KIBRA and memory , 2009, Neuroscience Letters.

[45]  T. Ohtsuka,et al.  KIBRA Co-Localizes with Protein Kinase Mζ (PKMζ) in the Mouse Hippocampus , 2009 .

[46]  T. Ohtsuka,et al.  KIBRA Co-localizes with protein kinase Mzeta (PKMzeta) in the mouse hippocampus. , 2009, Bioscience, biotechnology, and biochemistry.

[47]  S. Johannsen,et al.  Temporal-spatial expression and novel biochemical properties of the memory-related protein KIBRA , 2008, Neuroscience.

[48]  Z. Khachaturian.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[49]  Hans-Jürgen Möller,et al.  Failure to replicate effect of kibra on human memory in two large cohorts of European origin , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[50]  F. Jessen,et al.  KIBRA gene variants are associated with episodic memory in healthy elderly , 2008, Neurobiology of Aging.

[51]  Sandro Sorbi,et al.  KIBRA gene variants are associated with episodic memory performance in subjective memory complaints , 2008, Neuroscience Letters.

[52]  R. Lipton,et al.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.

[53]  S. Schwab,et al.  KIBRA genetic polymorphism influences episodic memory in later life, but does not increase the risk of mild cognitive impairment , 2008, Journal of cellular and molecular medicine.

[54]  Jason J. Corneveaux,et al.  Common Kibra Alleles Are Associated with Human Memory Performance , 2006, Science.

[55]  A. R.,et al.  Review of literature , 1951, American Potato Journal.

[56]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[57]  A. Barnekow,et al.  KIBRA is a novel substrate for protein kinase Czeta. , 2004, Biochemical and biophysical research communications.

[58]  J. Krystal,et al.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. , 2004, Archives of general psychiatry.

[59]  Thomas Liedtke,et al.  Characterization of KIBRA, a novel WW domain-containing protein. , 2003, Biochemical and biophysical research communications.

[60]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[61]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.

[62]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[63]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[64]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.